JP2017523143A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017523143A5 JP2017523143A5 JP2016572643A JP2016572643A JP2017523143A5 JP 2017523143 A5 JP2017523143 A5 JP 2017523143A5 JP 2016572643 A JP2016572643 A JP 2016572643A JP 2016572643 A JP2016572643 A JP 2016572643A JP 2017523143 A5 JP2017523143 A5 JP 2017523143A5
- Authority
- JP
- Japan
- Prior art keywords
- nhc
- independently selected
- alkyl
- heteroatoms
- linked
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229940127121 immunoconjugate Drugs 0.000 claims 20
- 125000005842 heteroatom Chemical group 0.000 claims 14
- 150000001875 compounds Chemical class 0.000 claims 12
- 125000001424 substituent group Chemical group 0.000 claims 7
- 125000006582 (C5-C6) heterocycloalkyl group Chemical group 0.000 claims 6
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 3
- 125000003831 tetrazolyl group Chemical group 0.000 claims 3
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 239000000427 antigen Substances 0.000 claims 2
- 102000036639 antigens Human genes 0.000 claims 2
- 108091007433 antigens Proteins 0.000 claims 2
- 230000008878 coupling Effects 0.000 claims 2
- 238000010168 coupling process Methods 0.000 claims 2
- 238000005859 coupling reaction Methods 0.000 claims 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims 1
- 125000006588 heterocycloalkylene group Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- -1 —C (═O) OR 12 Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462011961P | 2014-06-13 | 2014-06-13 | |
| US62/011,961 | 2014-06-13 | ||
| PCT/IB2015/054400 WO2015189791A1 (en) | 2014-06-13 | 2015-06-11 | Auristatin derivatives and conjugates thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2017523143A JP2017523143A (ja) | 2017-08-17 |
| JP2017523143A5 true JP2017523143A5 (OSRAM) | 2018-07-19 |
| JP6681346B2 JP6681346B2 (ja) | 2020-04-15 |
Family
ID=53491655
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016572643A Expired - Fee Related JP6681346B2 (ja) | 2014-06-13 | 2015-06-11 | オーリスタチン誘導体およびその抱合体 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US9884817B2 (OSRAM) |
| EP (1) | EP3154997B9 (OSRAM) |
| JP (1) | JP6681346B2 (OSRAM) |
| KR (1) | KR20170016479A (OSRAM) |
| CN (1) | CN106573956A (OSRAM) |
| AU (1) | AU2015273098B2 (OSRAM) |
| BR (1) | BR112016028835A2 (OSRAM) |
| CA (1) | CA2951368A1 (OSRAM) |
| EA (1) | EA201692530A1 (OSRAM) |
| IL (1) | IL248961A0 (OSRAM) |
| MX (1) | MX2016016515A (OSRAM) |
| SG (1) | SG11201609462RA (OSRAM) |
| WO (1) | WO2015189791A1 (OSRAM) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102447350B1 (ko) * | 2013-02-08 | 2022-09-23 | 노파르티스 아게 | 면역접합체의 제조를 위한 항체의 변형에 사용되는 특정 부위 |
| AU2014384434B2 (en) * | 2014-02-28 | 2016-11-03 | Hangzhou Dac Biotech Co., Ltd | Charged linkers and their uses for conjugation |
| US9884817B2 (en) * | 2014-06-13 | 2018-02-06 | Novartis Ag | Auristatin derivatives and conjugates thereof |
| US11566082B2 (en) | 2014-11-17 | 2023-01-31 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| MA44334A (fr) | 2015-10-29 | 2018-09-05 | Novartis Ag | Conjugués d'anticorps comprenant un agoniste du récepteur de type toll |
| US10654887B2 (en) | 2016-05-11 | 2020-05-19 | Ge Healthcare Bio-Process R&D Ab | Separation matrix |
| US10730908B2 (en) | 2016-05-11 | 2020-08-04 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| ES2909833T3 (es) | 2016-05-11 | 2022-05-10 | Cytiva Bioprocess R & D Ab | Método de limpieza y/o desinfección de una matriz de separación |
| US11708390B2 (en) | 2016-05-11 | 2023-07-25 | Cytiva Bioprocess R&D Ab | Method of storing a separation matrix |
| US10703774B2 (en) | 2016-09-30 | 2020-07-07 | Ge Healthcare Bioprocess R&D Ab | Separation method |
| US10889615B2 (en) | 2016-05-11 | 2021-01-12 | Cytiva Bioprocess R&D Ab | Mutated immunoglobulin-binding polypeptides |
| EP3455243B1 (en) | 2016-05-11 | 2021-03-24 | Cytiva BioProcess R&D AB | Separation matrix |
| JP7031934B2 (ja) | 2016-05-11 | 2022-03-08 | サイティバ・バイオプロセス・アールアンドディ・アクチボラグ | 分離マトリックス |
| US12448411B2 (en) | 2016-09-30 | 2025-10-21 | Cytiva Bioprocess R&D Ab | Separation method |
| JOP20190155A1 (ar) * | 2016-12-21 | 2019-06-23 | Novartis Ag | مترافقات عقار جسم مضاد لإزالة خلايا جذعية مكونة للدم |
| JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
| CA3081925A1 (en) * | 2017-11-18 | 2019-05-23 | Nzola DE MAGALHAES | Product and process for employing gc7 (n1-guanyl-1,7-diaminoheptane) based antigen binding conjugates in cancer therapy |
| KR102834656B1 (ko) * | 2019-09-29 | 2025-07-17 | 맙플렉스 인터내셔널 컴퍼니 리미티드 | 산 방법에 의한 항체-약물 접합체 중간체의 제조 방법 및 이의 적용 |
| CN113321702B (zh) * | 2020-02-28 | 2022-08-05 | 国家纳米科学中心 | 一种单甲基澳瑞他汀f甲酯前药及其制备方法和应用 |
| US20230181756A1 (en) | 2020-04-30 | 2023-06-15 | Novartis Ag | Ccr7 antibody drug conjugates for treating cancer |
| CN111675694B (zh) * | 2020-06-28 | 2021-11-26 | 山东大学 | 一种含肟基团的二芳基嘧啶类hiv-1逆转录酶抑制剂及其制备方法与应用 |
| WO2022217022A1 (en) | 2021-04-10 | 2022-10-13 | Profoundbio Us Co. | Folr1 binding agents, conjugates thereof and methods of using the same |
| CN117203238A (zh) | 2021-04-23 | 2023-12-08 | 普方生物制药美国公司 | Cd70结合剂、其偶联物及其使用方法 |
| TW202320857A (zh) | 2021-07-06 | 2023-06-01 | 美商普方生物製藥美國公司 | 連接子、藥物連接子及其結合物及其使用方法 |
| WO2023061405A1 (zh) * | 2021-10-12 | 2023-04-20 | 成都科岭源医药技术有限公司 | 一种高稳定性的靶向接头-药物偶联物 |
| KR20240152826A (ko) * | 2021-12-23 | 2024-10-22 | 애드센트릭스 테라퓨틱스 잉크. | 신규한 오리스타틴 유사체 및 이의 면역접합체 |
| AR133955A1 (es) | 2023-09-26 | 2025-11-19 | Profoundbio Us Co | Agentes de unión a ptk7, conjugados de éstos y métodos de uso de los mismos |
| WO2025149661A1 (en) | 2024-01-10 | 2025-07-17 | Genmab A/S | Slitrk6 binding agents, conjugates thereof and methods of using the same |
| CN120309684A (zh) * | 2024-01-15 | 2025-07-15 | 武汉人福创新药物研发中心有限公司 | 靶向化合物及其用途 |
| WO2025181219A1 (en) | 2024-02-29 | 2025-09-04 | Genmab A/S | Egfr and c-met bispecific binding agents, conjugates thereof and methods of using the same |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
| EP0598129B1 (en) | 1991-08-09 | 2000-03-22 | Teikoku Hormone Mfg. Co., Ltd. | Novel tetrapeptide derivative |
| DE69434136T2 (de) | 1993-10-01 | 2005-12-01 | Teikoku Hormone Mfg. Co., Ltd. | Dolastatin-derivate |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| AU704973B2 (en) | 1995-04-21 | 1999-05-13 | Teikoku Hormone Mfg. Co., Ltd. | Novel peptide derivatives |
| EP0985039B1 (en) | 1997-06-12 | 2008-02-20 | Novartis International Pharmaceutical Ltd. | Artificial antibody polypeptides |
| US6153655A (en) | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
| US7803915B2 (en) | 2001-06-20 | 2010-09-28 | Genentech, Inc. | Antibody compositions for the diagnosis and treatment of tumor |
| US20090068178A1 (en) | 2002-05-08 | 2009-03-12 | Genentech, Inc. | Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin |
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| NZ583292A (en) | 2003-11-06 | 2012-03-30 | Seattle Genetics Inc | Monomethylvaline compounds capable of conjugation to ligands |
| AU2005332660A1 (en) * | 2004-11-12 | 2006-12-14 | Seattle Genetics, Inc. | Auristatins having an aminobenzoic acid unit at the N terminus |
| AU2005316844A1 (en) | 2004-11-29 | 2006-06-22 | Seattle Genetics, Inc. | Engineered antibodies and immunoconjugates |
| US20070160617A1 (en) | 2005-06-20 | 2007-07-12 | Psma Development Company, Llc | PSMA antibody-drug conjugates |
| US7750116B1 (en) | 2006-02-18 | 2010-07-06 | Seattle Genetics, Inc. | Antibody drug conjugate metabolites |
| WO2007103288A2 (en) | 2006-03-02 | 2007-09-13 | Seattle Genetics, Inc. | Engineered antibody drug conjugates |
| AR059900A1 (es) | 2006-03-17 | 2008-05-07 | Genentech Inc | Anticuerpos anti-tat226 e inmunoconjugados |
| CN101903403B (zh) | 2007-10-19 | 2016-03-16 | 西雅图基因公司 | Cd19结合剂及其应用 |
| DK2842575T3 (da) | 2008-03-18 | 2017-11-27 | Seattle Genetics Inc | Auristatin-lægemiddel-linker-konjugater |
| ES2553874T3 (es) | 2010-09-29 | 2015-12-14 | Seattle Genetics, Inc. | N-Carboxialquil-auristatinas y su uso |
| ES3004351T3 (en) | 2010-10-22 | 2025-03-12 | Seagen Inc | Synergistic effects between auristatin-based antibody drug conjugates and inhibitors of the pi3k-akt mtor pathway |
| EP2678037B1 (en) | 2011-02-25 | 2014-12-03 | Lonza Ltd | Branched linker for protein drug conjugates |
| ES2543888T3 (es) | 2011-03-16 | 2015-08-25 | Seattle Genetics, Inc. | N-carboxialquil-auristatinas y su utilización |
| TWI582112B (zh) | 2011-04-21 | 2017-05-11 | 西雅圖遺傳學公司 | 新穎結合劑－藥物接合物（ＡＤＣｓ）及其用途（二） |
| US9796754B2 (en) | 2011-05-27 | 2017-10-24 | Ambrx, Inc. | Compositions containing, methods involving, and uses of non-natural amino acid linked dolastatin derivatives |
| JP2013100803A (ja) | 2011-08-09 | 2013-05-23 | Toru Shinohara | 水力発電装置および水力発電システム |
| PT3327027T (pt) * | 2011-11-17 | 2021-02-15 | Pfizer | Péptidos citotóxicos e seus conjugados de anticorpos e fármacos |
| WO2013092998A1 (en) | 2011-12-23 | 2013-06-27 | Innate Pharma | Enzymatic conjugation of antibodies |
| WO2013170272A2 (en) | 2012-05-11 | 2013-11-14 | Alexander Krantz | Site-specific labeling and targeted delivery of proteins for the treatment of cancer |
| AU2013271952A1 (en) | 2012-06-04 | 2014-11-13 | Irm Llc | Site-specific labeling methods and molecules produced thereby |
| EP2934596A1 (en) | 2012-12-21 | 2015-10-28 | Glykos Finland Oy | Linker-payload molecule conjugates |
| EP3753578A1 (en) * | 2013-12-17 | 2020-12-23 | Novartis AG | Cytotoxic peptides and conjugates thereof |
| US9884817B2 (en) * | 2014-06-13 | 2018-02-06 | Novartis Ag | Auristatin derivatives and conjugates thereof |
-
2015
- 2015-06-11 US US15/317,532 patent/US9884817B2/en active Active
- 2015-06-11 CA CA2951368A patent/CA2951368A1/en not_active Abandoned
- 2015-06-11 BR BR112016028835A patent/BR112016028835A2/pt not_active Application Discontinuation
- 2015-06-11 MX MX2016016515A patent/MX2016016515A/es unknown
- 2015-06-11 SG SG11201609462RA patent/SG11201609462RA/en unknown
- 2015-06-11 WO PCT/IB2015/054400 patent/WO2015189791A1/en not_active Ceased
- 2015-06-11 AU AU2015273098A patent/AU2015273098B2/en not_active Expired - Fee Related
- 2015-06-11 JP JP2016572643A patent/JP6681346B2/ja not_active Expired - Fee Related
- 2015-06-11 KR KR1020177000694A patent/KR20170016479A/ko not_active Withdrawn
- 2015-06-11 EP EP15732439.3A patent/EP3154997B9/en active Active
- 2015-06-11 CN CN201580043354.7A patent/CN106573956A/zh active Pending
- 2015-06-11 EA EA201692530A patent/EA201692530A1/ru unknown
-
2016
- 2016-11-14 IL IL248961A patent/IL248961A0/en unknown
-
2017
- 2017-11-27 US US15/822,930 patent/US10280139B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017523143A5 (OSRAM) | ||
| JP2018135343A5 (OSRAM) | ||
| RU2019130519A (ru) | 4-пиридоновое соединение или его соль, фармацевтическая композиция и содержащий их состав | |
| JP2015057390A5 (OSRAM) | ||
| JP2018537413A5 (ja) | 化合物、医薬的に許容される塩又はその立体異性体及び医薬組成物 | |
| JP2012522729A5 (OSRAM) | ||
| JP2016506960A5 (OSRAM) | ||
| RU2020131276A (ru) | Терапевтические соединения и композиции | |
| JP2016130266A5 (OSRAM) | ||
| JP2014521688A5 (OSRAM) | ||
| JP2016531126A5 (OSRAM) | ||
| JP2014515349A5 (OSRAM) | ||
| JP2016506958A5 (OSRAM) | ||
| RU2014114466A (ru) | ИНДАЗОЛ-3-КАРБОКСАМИДЫ И ИХ ПРИМЕНЕНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ СИГНАЛЬНОГО ПУТИ WNT/β-КАТЕНИНА | |
| JP2011500550A5 (OSRAM) | ||
| JP2018510139A5 (OSRAM) | ||
| JP2016526558A5 (OSRAM) | ||
| JP2016515561A5 (OSRAM) | ||
| JP2017537940A5 (OSRAM) | ||
| JP2017503833A5 (OSRAM) | ||
| JP2014015465A5 (OSRAM) | ||
| JP2016506962A5 (OSRAM) | ||
| JP2016540742A5 (OSRAM) | ||
| AR117189A1 (es) | Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb) | |
| JP2014526533A5 (OSRAM) |